Abiraterone, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen receptor inhibitor, Anticancer agents, Biochemical recurrence, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, Castrate-resistanter, Castration-resistant, Clinical trials, cSP, Deferred treatment, Diagnosis, Docetaxel, Enzalutamide, Focal therapy, Genomic classifier, Guidelines, HORRAD, HRQL, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Local radiotherapy, Localised, Localized, Lymphadenectomy, Mapping, Mass spectrometry, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, Mortality reduction, mp-MRI, MRI, Nomogram, Noncastrate, Overdiagnosis, Positron emission tomography, Pretreatment tables, Primary tumor treatment, Prognosis, Prostasomes, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, Proteomics, PSA, PSA flare, PSA kinetics, PSA screening, PTEN, Radiation therapy, Radical prostatectomy, Randomized trial, Randomized trials, Rapid metastasis, Receptors, Risk stratification, Robotic prostatectomy, Robotic surgery, Robotics, Salvage therapy, Screening, Sentinel lymph node, SREs, STAMPEDE, Surgical margins, Systematic review, Transcriptome, Transperineal template biopsy, Ultrasensitive PSA, Urinary incontinence, Urological surgery, WCRF/AICR CUP, Zoledronic acid